Budget Amount *help |
¥24,050,000 (Direct Cost: ¥18,500,000、Indirect Cost: ¥5,550,000)
Fiscal Year 2019: ¥7,800,000 (Direct Cost: ¥6,000,000、Indirect Cost: ¥1,800,000)
Fiscal Year 2018: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Fiscal Year 2017: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
|
Outline of Final Research Achievements |
In this study, we investigated the relationship between the increased plasma retinol levels in chronic kidney disease (CKD) and the epigenetic modification of fibroblast growth factor 23 (FGF23) gene. From the experiment of the administration of all-trans retinoic acid (ATRA) and retinoic acid receptor (RAR)-selective antagonists to CKD model mice, we suggested that ATRA may alleviate elevated plasma FGF23 levels through RARγ in CKD. In addition, lucifearase assay indicated that histone deacetylase (HDAC) may get involved in the depression effect of RA on the FGF23 gene promoter activity through RARγ. Together, these results suggest that retinol may contribute to the alleviation of the abnormal elevation of plasma FGF23 levels in CKD.
|